NCT04341246View on ClinicalTrials.gov

Characterization and Technical Evaluation of cT1 for NASH (CATE-NASH)

CompletedOBSERVATIONAL
Enrollment

28

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

June 12, 2023

Study Completion Date

June 12, 2023

Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
DEVICE

LiverMultiscan

The Livermultiscan is a quick, 15 minute contrast free MRI scan that provided metrics to quantify liver health namely fat, iron and fibro-inflammation

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

lead

Perspectum

INDUSTRY

NCT04341246 - Characterization and Technical Evaluation of cT1 for NASH (CATE-NASH) | Biotech Hunter | Biotech Hunter